Thymosin α 1 for treatment of hepatitis C virus: Promise and proof

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 136-140

  Sherman, Kenneth E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C virus; SVR; Thymosin 1; Treatment

Indexed keywords

ALPHA INTERFERON; INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; THYMOSIN ALPHA1;

CHRONIC HEPATITIS; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

HEPATITIS C VIRUS;

EID: 77951832245     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05460.x     Document Type: Conference Paper

References (26)

1. Choo, Q.L., G.Kuo, A.J. Weiner, et al. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.
2. Keller, BC, C.L. Johnson, A.K. Erickson & M. Gale Jr. 2007. Innate immune evasion by hepatitis C virus and West Nile virus.Cytokine Growth Factor Rev. 18: 535-544.
3. Johnson, C.L., D.M. Owen & M. Gale, Jr. 2007. Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J. Biol. Chem. 282: 10792-10803.
4. Saito, T. & M. Gale, Jr. 2008. Regulation of innate immunity against hepatitis C virus infection. Hepatol. Res. 38: 115-122.
5. Rashkin, S, S. Rouster, Z.D. Goodman & K.E. Sherman. 2009. T-helper cells and liver fibrosis in hepatitis C virusmonoinfected patients. J. Viral. Hepatol. 17: 222-226.
6. Alter, M.J. 2007. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13: 2436-2441.
7. Hoofnagle, J.H., K.D. Mullen, D.B. Jones, et al. 1986. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315: 1575-1578.
8. Fried, M.W., M.L. Shiffman, K.R. Reddy, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982.
9. Hadziyannis, S.J., H. Sette, Jr., T.R. Morgan, et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann. Intern.Med. 140: 346-355.
10. Heathcote, E.J., M.L. Shiffman, W.G. Cooksley, et al. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343: 1673-1680.
11. Manns, M.P., J.G.McHutchison, S.C. Gordon, et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
12. Matsumoto, A., E. Tanaka, T. Suzuki, et al. 1994. Viral and host factors that contribute to efficacy of interferonalpha 2a therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 39: 1273-1280.
13. McHutchison, J.G., S.C. Gordon, E.R. Schiff, et al. 1998. Interferon alfa-2b alone or in combinationwith ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments]. N. Engl. J. Med. 339: 1485-1492.
14. Hunt, C.M., J.A. Dominitz, B.P. Bute, et al. 1997. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig. Dis. Sci. 42: 2482-2486.
15. McHutchison, J.G., J.E.Ware, Jr., M.S. Bayliss, et al. 2001. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J. Hepatol. 34: 140-147.
16. Andreone, P., C. Cursaro, A. Gramenzi, et al. 1996. A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver 16: 207-210.
17. Andreone, P., C. Cursaro, A. Gramenzi, et al. 1996. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 24: 774-777.
18. Sherman, K.E., M. Sjogren, R.L. Creager, et al. 1998. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial. Hepatology 27: 1128-1135.
19. Sherman, K.E. & S.N. Sherman, S. 1998. Interferon plus thymosin alpha-1 treatment of chronic hepatitis C infection: a meta-analysis. In Therapies for Viral Hepatitis. R.F. Schinazi, J.-P. Sommadossi & H.C. Thomas, Eds.: 379-383. International Medical Press. London.
20. Andreone, P., A. Gramenzi, C. Cursaro, et al. 2004. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: Results of a randomized controlled pilot trial. J. Viral Hepat. 11: 69-73.
21. Sherman, K.E., S.C. Gordon, R. Iftikar, et al. 2007. Retreatment of treatment experienced HCV patients with pegylated interferon alfa-2A and thymosin alpha- 1: pooled analysis of two randomized controlled trials. Hepatology 46(Suppl 1) (Abstr.): 1331.
22. Hezode, C., N. Forestier, G. Dusheiko, et al. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360: 1839-1850.
23. McHutchison, J.G., G.T. Everson, S.C. Gordon, et al. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J.Med. 360: 1827-1838.
24. Poo, J.L., F. Sanchez Avila, D. Kershenobich, et al. 2008. Efficacy of triple therapywith thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. Ann. Hepatol. 7: 369-375.
25. Abbas, Z., S.S. Hamid, S. Tabassum & W. Jafri. 2004. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronichepatitisCpatientswho are nonresponders or relapsers to interferon alpha plus ribavirin. J. Pak. Med. Assoc. 54: 571-574.
26. Garcia-Contreras, F., A. Nevarez-Sida, P. Constantino- Casas, et al. 2006. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1. Arch. Med. Res. 37: 663-673.